

(vaginal; tuberculosis **vaccine** formulation)  
 IT Polymers, biological studies  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (water-absorbing; tuberculosis **vaccine** formulation)  
 IT 112-80-1, Oleic acid, biological studies 25496-72-4, Monoolein  
 53026-40-7D, **Arabinomannan**, lipid derivs.  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (tuberculosis **vaccine** formulation)

=> d his

(FILE 'HOME' ENTERED AT 16:03:07 ON 14 APR 2004)  
 SET COST OFF

FILE 'WPIX' ENTERED AT 16:03:16 ON 14 APR 2004

L1 1 S (WO2000-NZ27 OR NZ99-334664)/AP,PRN  
 E MALAGHAN/PA,CS  
 L2 4 S E3-E6  
 E OTAGO/PA,CS  
 L3 35 S E3,E4  
 E LE GROS G/AU  
 L4 4 S E4  
 E LEGROS G/AU  
 L5 1 S E3  
 E SCANGA C/AU  
 L6 2 S E3,E4  
 E BEASLEY C/AU  
 L7 5 S E3,E8  
 E HARPER J/AU  
 L8 38 S E3,E18  
 E SHIRTCLIFFE P/AU  
 L9 1 S E3  
 L10 107 S A61K031-739/IC,ICM,ICS  
 L11 0 S A61K031-739/ICA,ICI  
 L12 270 S (B04-C02V OR C04-C02V)/MC  
 L13 136 S (?LIPOARABINOMANNAN? OR ?ARABINOMANN? OR ?ARABIN?(L)?MANNAN?)  
 E RA0121/DCN  
 E E 3+ALL  
 E RA0121+ALL/DCN  
 L14 495 S L10,L12,L13  
 L15 22 S L14 AND ?ASTHMA?/BIX  
 L16 15 S L14 AND (B14-K01A OR C14-K01A)/MC  
 L17 0 S L14 AND (B12-K02 OR C12-K02)/MC  
 L18 1 S L14 AND (B12-D02 OR C12-D02)/MC  
 L19 21 S L14 AND P822/M0,M1,M2,M3,M4,M5,M6  
 L20 4 S L14 AND A61P011-06/IC,ICM,ICS,ICA,ICI  
 L21 28 S L15-L20  
 L22 3 S L14 AND (A61K009-12/IC,ICM,ICS,ICA,ICI OR A61K009:12/ICA,ICI)  
 L23 8 S L14 AND (R012 OR R011 OR R010)/M0,M1,M2,M3,M4,M5,M6  
 L24 3 S L14 AND (B12-M01B OR C12-M01B)/MC  
 L25 11 S L22-L24  
 L26 3 S L21 AND L25  
 L27 33 S L21,L25 NOT L26  
 L28 7 S L13 AND L27  
 L29 6 S L28 NOT INCENSOLE/TI  
 L30 7 S L1,L29 AND L1-L29  
 L31 77 S L2-L9  
 L32 1 S L31 AND L14  
 L33 4 S L31 AND ?ASTHMA?/BIX

L34 5 S L31 AND (A61P011/IC,ICM,ICS,ICA,ICI OR P822/M0,M1,M2,M3,M4,M5  
L35 5 S L32-L34  
L36 11 S L30,L35  
L37 324 S (M OR MYCOBACTER? OR MYCO BACTER?)( )BOVIS/BIX  
L38 3409 S (MYCOBACTER? OR MYCO BACTER?)/BIX  
L39 3439 S L37,L38  
L40 40 S L39 AND L14  
L41 1 S L40 AND (A61K009-12/IC,ICM,ICS,ICA,ICI OR A61K009:12/ICA,ICI)  
L42 2 S L40 AND (R012 OR R011 OR R010)/M0,M1,M2,M3,M4,M5,M6  
L43 2 S L40 AND (B12-M01B OR C12-M01B)/MC  
L44 4 S L41-L43  
L45 12 S L36,L44 AND L1-L44

FILE 'WPIX' ENTERED AT 16:25:27 ON 14 APR 2004

FILE 'MEDLINE' ENTERED AT 16:25:53 ON 14 APR 2004

L46 500 S ?LIPOARABINOMANNAN? OR ?ARABINOMANN? OR ?ARABIN?(L)?MANNAN?  
L47 574 S ARABINOSE AND MANNOSE  
L48 1047 S L46,L47  
L49 0 S L48 AND ?ASTHMA?  
E ASTHMA/CT  
E E3+ALL  
L50 0 S L48 AND E15+NT  
L51 17 S L48 AND E27+NT  
L52 36 S L48 AND C20./CT  
L53 53 S L51,L52  
E L53 AND PY<=1999  
L54 32 S L53 AND PY<=1999  
L55 21 S L53 NOT L54

FILE 'EMBASE' ENTERED AT 16:30:00 ON 14 APR 2004

L56 480 S L46  
L57 449 S L47  
L58 38472 S LIPOPOLYSACCHARIDE OR LIPO POLYSACCHARIDE  
L59 909 S L56,L57  
L60 1 S L59 AND ?ASTHMA?  
E ASTHMA/CT  
E E3+ALL  
L61 69232 S E14+NT  
L62 1 S L59 AND L61  
L63 1 S L60,L62  
L64 225 S L58 AND L61  
L65 270 S L58 AND ?ASTHMA?  
L66 270 S L64,L65  
L67 4 S L66 AND (MYCOBACTER? OR MYCO BACTER?)  
L68 5 S L63,L67

FILE 'EMBASE' ENTERED AT 16:33:05 ON 14 APR 2004

FILE 'BIOSIS' ENTERED AT 16:33:15 ON 14 APR 2004

L69 1868 S L46 OR L47  
L70 2 S L69 AND ?ASTHMA?  
L71 61296 S MYCOBACTERIACEAE+NT/ORGAN  
L72 471 S L69 AND L71  
L73 7 S L72 AND (?ASTHMA? OR ?BRONCH?)  
E LE GROS G/AU  
L74 72 S E3-E7  
E LEGROS G/AU  
L75 23 S E3,E4,E5  
E SCANGA C/AU  
L76 5 S E3,E5,E8  
E BEASLEY C/AU  
L77 51 S E3,E12,E13,E18,E22

E HARPER J/AU  
L78 230 S E3,E17  
L79 7 S E30,E31  
E SHIRTCLIFFE P/AU  
L80 8 S E3-E7  
L81 0 S L69 AND L74-L80  
L82 28 S ?ASTHMA? AND L74-L80  
L83 6 S L71 AND L82  
L84 271 S L71 AND ?ASTHMA?  
L85 24 S L84 AND VACCIN?  
L86 27 S L70,L73,L82,L83,L85 AND PY<=1999

FILE 'HCAPLUS' ENTERED AT 16:39:44 ON 14 APR 2004

L87 1 S L1  
L88 975 S L46  
L89 742 S L88 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L90 1 S L89 AND ?ASTHMA?  
E ASTHMA/CT  
L91 1 S E3-E5 AND L88  
E E3+ALL  
L92 1 S E8+NT AND L88  
E E11+ALL  
L93 2 S E6,E5+NT AND L88  
L94 1 S L89 AND L87,L90-L93  
E VACCINES/CT  
E E3+ALL  
L95 37572 S E4  
L96 12 S L95 AND L89  
L97 12 S L96 AND MYCOBACT?  
L98 12 S L94,L97  
E LEGROSG/AU  
E LEGROS G/AU  
L99 4 S E6,E7  
E LE GROS G/AU  
L100 60 S E3-E8  
E SCANGA C/AU  
L101 4 S E4,E9,E10  
E BEASLEY C/AU  
L102 2 S E3,E10  
L103 9 S E13,E20,E21  
E HARPER J/AU  
L104 58 S E3,E18  
L105 9 S E32-E34  
E SHIRTCLIFFE P/AU  
L106 2 S E4  
L107 1 S L88 AND L99-L106  
L108 12 S L98,L107  
L109 12 S L108 AND VACCIN?  
L110 2 S L109 AND (?BRONCH? OR LUNG OR ?ASTHMA? OR RESPIR? OR ?INHAL?

FILE 'HCAPLUS' ENTERED AT 16:45:58 ON 14 APR 2004

=> => s l109 not l110  
L111 10 L109 NOT L110

=> d all tot

L111 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:391938 HCAPLUS  
DN 135:4466  
ED Entered STN: 31 May 2001  
TI Presentation of hydrophobic antigens to T-cells by CD1 molecules